Lundbeck today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to asedebart (Lu AG13909), Lundbeck's novel investigational anti-ACTH monoclonal ...

Danish drugmaker Lundbeck has received orphan drug status, Orphan Drug Designation, from the US FDA for asedebart, Lu AG13909, for the treatment of endogenous Cushing's syndrome. Asedebart is an ...

Cushing disease occurs when benign tumors on the pituitary gland release excess adrenocorticotropic hormone (ACTH), leading to high cortisol levels. Cushing syndrome is the name for the disorder or ...

Lundbeck A/S announced that the U.S. FDA has granted Orphan Drug Designation to its investigational antibody Asedebart (Lu AG13909) for the treatment of endogenous Cushing's syndrome.

US FDA grants orphan drug designation for Lundbeck’s investigational anti-ACTH monoclonal antibody asedebart to treat endogenous Cushing’s syndrome: Valby, Denmark Saturday, S ...